Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary
The DOI matches its Crossref record; 123 of the 130 references it cites were found in a registry or an index.
Abstract
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a)…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence favors the need to assess apo Becontaining lipoproteins to account for remnant lipoproteins and small dense lipoproteins responsible for residual ASCVD risk not seen with a standard lipid panel of total cholesterol, LDL-C, and HDL-C.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [314]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 6×
“Outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in which achieved LDL-C levels were substantially lower than those in statin trials further reinforced the notion that “lower is better” (24,25).”
InfluentialThe Health consequences of smoking—50 years of progress : a report of the Surgeon General
Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Research works printed but not linked: 4
- Sever, 2003, J Am Coll Cardiol., 361, 1149
- Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Cardiovasc Diabetol., 366, 1849
- 2000, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease, N Engl J Med., 102, 21
- Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet., 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationSamson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Lipoprotein(a) and cardiovascular disease
Nordestgaard, B. G., & Langsted, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01308-4 · Cited by 288
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds
Tsimikas, S., & Marcovina, S. M. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.019 · Cited by 176
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Ten things to know about ten cardiovascular disease risk factors – 2022
Bays, H. E., Agarwala, A., German, C. A., Satish, P., Iluyomade, A., Dudum, R., Thakkar, A., Rifai, M. A., Mehta, A., Thobani, A., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100342 · Cited by 171
“[93] Table 10b Simon Broome diagnostic criteria for Familial Hypercholesterolemia [451, 444] Definite Familial Hypercholesterolemia: • Adult with total cholesterol levels ≥ 290 mg/dL (> 7.5 mmol/L) or LDL-C ≥ 190 mg/dL (> 4.9 mmol/L) • Child < 16 years of age with total cholesterol levels ≥ 260 mg/dL (> 6.7 mmol/L) or…”
BackgroundInfluentialLipoprotein(a) Testing Trends in a Large Academic Health System in the United States
Bhatia, H. S., Hurst, S., Desai, P., Zhu, W., & Yeang, C. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031255 · Cited by 135
Soffer, D. E., Marston, N. A., Maki, K. C., Jacobson, T. A., Bittner, V. A., Peña, J. M., Thanassoulis, G., Martin, S. S., Kirkpatrick, C. F., Virani, S. S., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.08.013 · Cited by 115
Wang, S., Ren, H., Zhong, H., Zhao, X., Li, C., Ma, J., Gu, X., Xue, Y., Huang, S., Yang, J., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.2003176 · Cited by 122
Mazhar, F., Faucon, A., Fu, E. L., Szummer, K. E., Mathisen, J., Gerward, S., Reuter, S. B., Marx, N., Mehran, R., & Carrero, J. J. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae557 · Cited by 99
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationNadolsky, K., Addison, B., Agarwal, M., Almandoz, J. P., Bird, M. D., DeGeeter Chaplin, M., Garvey, W. T., & Kyle, T. K. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.03.272 · Cited by 86
Underberg, J., Toth, P. P., & Rodriguez, F. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2117498 · Cited by 78
“ACC/AHA guideline on the primary prevention of CVD [38] ESC guidelines on the management of dyslipidemias [62], ACS [39], and diabetes, pre-diabetes, and CVD [63] AACE/ACE consensus statement on the management of dyslipidemia and prevention of CVD [40] ESC/EAS guidelines [62] Target <40 mg/dL if a patient sustains a r…”
MethodHigh lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 92
“…2019 European Society of Cardiology/EAS (ESC/EAS) [81] dyslipidemia guidelines, and by scientific or consensus statements from the National Lipid Association (NLA) [4] and the American Association of Clinical Endocrinologists and American College on Endocrinology (AACE/ACE) [31], respectively (Fig.”
BackgroundMethodInfluentialApolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice
Oliveira-Gomes, D. D., Joshi, P. H., Peterson, E. D., Rohatgi, A. K., Khera, A., & Návar, A. M. (2024) · Circulation · doi:10.1161/circulationaha.124.068885 · Cited by 101
“9 In the 2015 National Lipid Association recommendations for patient-centered management of dyslipidemia, the apoB recommendations are 80 mg/dL for high-risk patients and 90 mg/dL in primary prevention, both on the basis of NHANES III data.”
BackgroundPatel, S. B., Wyne, K. L., Afreen, S., Belalcazar, L. M., Bird, M. D., Coles, S., Marrs, J. C., Peng, C. C., Pulipati, V. P., Sultan, S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.016 · Cited by 85
Self-citationLeiter, L. A., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Mancini, G. B. J., Ray, K. K., Hanselman, J. C., Ye, Z., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14645 · Cited by 74
“Reducing LDL-C levels, primarily with the use of statins, is recommended for individuals with hypercholesterolaemia irrespective of glycaemic status.(2-6) Many individuals with insufficient LDL-C lowering or higher residual atherogenic risk may require further reduction in LDL-C, and/or non-HDL-C and other apolipoprot…”
BackgroundHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
“6,59 Myopathy and in rare cases rhabdomyolysis are the primary adverse effects of concern.”
InfluentialSelf-citationGenetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk
Volgman, A. S., Koschinsky, M. L., Mehta, A., & Rosenson, R. S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033654 · Cited by 80
Real‐world performance of the MiniMed™ 670G system in Europe
Da Silva, J., Bosi, E., Jendle, J., Arrieta, A., Castaneda, J., Grossman, B., Cordero, T. L., Shin, J., & Cohen, O. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14424 · Cited by 60
“5%), provided it can be achieved safely.(1,2) Additionally, professional societies have endorsed recommendations from an international consensus on durations of time spent in target glucose range,(3) as well as use of the calculated glucose management indicator (GMI), to approximate the levels of HbA1c.”
BackgroundNew Therapies for Primary Hyperlipidemia
Aguilar-Salinas, C. A., Gómez-Díaz, R. A., & Corral, P. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab876 · Cited by 57
Ballantyne, C. M., Banach, M., Bays, H. E., Catapano, A. L., Laufs, U., Stroes, E. S. G., Robinson, P. L., Lei, L., & Ray, K. K. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.03.020 · Cited by 58
Sanchez, R. J., Ge, W., Wei, W., Ponda, M. P., & Rosenson, R. S. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01488-8 · Cited by 51
Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
Basu, R., Noureddin, M., & Clark, J. M. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.04.005 · Cited by 50
Welsh, P. I., Zabiby, A. A., Byrne, H., Benbow, H. R., Itani, T., Farries, G., Costa‐Scharplatz, M., Ferber, P. C., Martin, L., Brown, R., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117437 · Cited by 41
Estándares SEA 2022 para el control global del riesgo cardiovascular
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2022) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.11.003 · Cited by 70
“Además de las terapias mediadas por la comunicación en la visita médica, incluyendo el consejo y la entrevista motiva-cional fármacos 134 y aumentan la probabilidad de abandono del tabaquismo 4 . un riesgo peque˜no (1/1.”
BackgroundLi, J., Dou, K., Zhou, Z., Zhao, D. H., Ye, P., Zhao, J., & Guo, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1069992 · Cited by 40
Gourdy, P., Schiele, F., Halimi, J., Kownator, S., Hadjadj, S., & Valensi, P. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1227769 · Cited by 35
“However, several clinical practice guidelines do not recommend carotid ultrasound IMT for ASCVD risk assessment due to its weak specificity and reproducibility (10, 13, 16).”
BackgroundMethodInfluentialSerum LDL-C/HDL-C ratio and the risk of carotid plaques: a longitudinal study
Wu, Z., Li, X., Qin, W., Tao, B., Qiu, B., Zhang, Q., & Wang, J. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02942-w · Cited by 43
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 50
Omega‐3 fatty acids for the prevention of atherosclerotic cardiovascular disease
Barry, A. R., & Dixon, D. L. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2615 · Cited by 36
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 51
Liu, L., Aimaiti, X., Zheng, Y.-Y., Zhi, X.-Y., Wang, Z.-L., Yin, X., Pan, Y.-B., Wu, T.-T., & Xie, X. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01876-2 · Cited by 34
“risk factors in the adolescent population, promoting reasonable exercise and a healthy diet are the key to preventing dyslipidemia [31].”
BackgroundLuo, Y., & Peng, D. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231189597 · Cited by 32
Loh, W. J., Chan, D. C., Mata, P., & Watts, G. F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.905941 · Cited by 32
Yu, H., Li, Y., Tao, L., Yang, L., Liu, D., Wang, Y., Hao, X., He, H., Che, Y., Wang, P., et al. (2022) · Nutrients · doi:10.3390/nu14153243 · Cited by 31
Kim, K., Hong, S., Han, K., & Park, C. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155327 · Cited by 33
Functional Roles of Furin in Cardio-Cerebrovascular Diseases
Wichaiyo, S., Koonyosying, P., & Morales, N. P. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00325 · Cited by 27
Chen, X., Hou, C., Yao, L., Li, J., Gui, M., Wang, M., Zhou, X., Lü, B., & Fu, D. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01914-z · Cited by 29
“Dyslipidemia comprises a range of conditions primarily defined by elevations in lipoprotein cholesterol, including low-density lipoprotein (LDL) and non-high-density lipoprotein cholesterol, as well as elevated triglycerides (TG) [1].”
BackgroundHuang, H., Yang, B., Yu, R., Ouyang, W., Tong, J., & Le, Y. (2024) · Nutrition Journal · doi:10.1186/s12937-024-00983-9 · Cited by 27
“And normal range of serum lipids levels are as follows: HDL ≥ 1.04 mmol/L (40 mg/ dL); LDL < 3.36 mmol/L (130 mg/dL); TC < 5.17 mmol/L (200 mg/dL); and TG < 3.88 mmol/L (150 mg/dL) [39].”
InfluentialMiller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 26
“American Association of Clinical Endocrinologists/ American College of Endocrinology – Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm (2020) [126] For patients treated with maximally tolerated statins who have established ASCVD or diabetes with ≥2 ASCVD risk factors and TG between 1.”
Self-citationZou, Q., Su, C., Du, W., Wang, H., Zhang, B., Luo, S., Tan, T., Song, X., Zhong, X., Zhang, H., et al. (2023) · Nutrients · doi:10.3390/nu15020341 · Cited by 24
Liu, S., Zhang, D., Ju, J., Wang, A., Du, T., Chen, X., Song, Y., Gao, Z., & Xu, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1260764 · Cited by 24
Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations
Ciffone, N. A., McNeal, C. J., McGowan, M. P., & Ferdinand, K. C. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100350 · Cited by 33
“Recommendations AACE/ACE [9] Test Lp(a) in the following populations: • All patients with clinical ASCVD or a family history of premature ASCVD and/or elevated Lp(a) • Patients with South Asian or African ancestry • Individuals with a 10-year ASCVD risk ≥ 10 % (primary prevention) • Patients with a…”
BackgroundSamson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 33
Puri, R., Mehta, V., Duell, P. B., Iyengar, S. S., Yusuf, J., Dalal, J., Narasingan, S. N., Kalra, D. K., Kapoor, A., Pradhan, A. K., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.008 · Cited by 24
Liao, Y., Dong, Z., Liao, H., Chen, Y., Hu, L., Yu, Z., Xia, Y. X., Zhao, Y., Fan, K., Ding, J., et al. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01696-w · Cited by 23
“It has been reported that more than half of the risk of CAD is associated with dyslipidaemia, and the increase in major blood lipid indicators is closely related to the occurrence of cardiovascular risk events [5].”
BackgroundLipoprotein(a): a genetically determined risk factor for Cardiovascular disease
Marcovina, S. M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2229915 · Cited by 28
New and Emerging lipid-lowering Therapy
Backes, J. M., & Hilleman, D. E. (2021) · Future Cardiology · doi:10.2217/fca-2020-0217 · Cited by 21
Elkhayat, D., Abdelmalak, N. S., Amer, R. I., & Awad, H. H. (2024) · ACS Omega · doi:10.1021/acsomega.3c08428 · Cited by 21
Worldwide Increasing Use of Nonfasting Rather Than Fasting Lipid Profiles
Langsted, A., & Nordestgaard, B. G. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae046 · Cited by 24
Lipoprotein(a) – From Biomarker to Therapy: A Review for the Clinician
Jha, M., Raber, I., & Gelfand, E. V. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.034 · Cited by 22
Pelacarsen: Mechanism of action and Lp(a)-lowering effect
Bhatia, H. S., Bajaj, A., Goonewardena, S. N., & Moriarty, P. M. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.004 · Cited by 43
The Inherited Hypercholesterolemias
Loh, W. J., & Watts, G. F. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.006 · Cited by 24
Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
Ballantyne, C. M., Bays, H. E., Louie, M. J., Smart, J., Zhang, Y., & Ray, K. K. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024531 · Cited by 23
Ali, H. I., Elmi, F., Stojanovska, L., Ibrahim, N., Ismail, L. C., & Dhaheri, A. S. A. (2022) · Nutrients · doi:10.3390/nu14163405 · Cited by 25
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
Nestel, P. J., Loh, W. J., Ward, N. C., & Watts, G. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac541 · Cited by 21
Statin intolerance management: a systematic review
Meza-Contreras, A., Wenczenovicz, C., Ruiz-Arellanos, K., Kinzelman-Vesely, E. A., Mogollon, R. J., & Montori, V. M. (2022) · Endocrine · doi:10.1007/s12020-022-03263-w · Cited by 19
Si, Y., Feng, Z., Liu, Y., Fan, W., Shan, W., Zhang, Y., Shi, F., Xing, E., & Sun, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-30035-x · Cited by 24
Patel, S. B., Belalcazar, L. M., Afreen, S., Balderas, R., Hegele, R. A., Karpe, F., Ponte-Negretti, C. I., & Rajpal, A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.014 · Cited by 23
Gao, B., Bao, Y., Meng, M., Yu, L., Lu, Y., Sa, R., Liang, X., & Shi, J. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107206 · Cited by 17
Song, R., Ren, C., Cheng, J., Li, C., & Yang, X. (2023) · Measurement · doi:10.1016/j.measurement.2023.113604 · Cited by 17
Lin, L., Kiryakos, J., Ammous, F., Ratliff, S. M., Ware, E. B., Faul, J. D., Kardia, S. L. R., Zhao, W., Birditt, K. S., & Smith, J. A. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01914-7 · Cited by 18
“Dyslip-idemia, a modifiable major risk factor for CVD [2–4], is characterized by decreased high-density lipoprotein-cholesterol (HDL-C), elevated low-density lipoprotein-cholesterol (LDL-C), and/or elevated triglycerides (TG) [5].”
BackgroundEidensohn, Y., Bhatla, A., Ding, J., Blumenthal, R. S., Martin, S. S., & Marvel, F. A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100686 · Cited by 19
“The NLA recommends testing Lp(a) in all patients with primary severe hypercholesterolemia (LDL-C ≥ 190 mg/dL) or premature ASCVD, which the AACE/ACE extends to all patients with ASCVD [15,16].”
BackgroundMethodStatin‐associated muscle symptoms—A review: Individualizing the approach to optimize care
Wiggins, B. S., Backes, J. M., & Hilleman, D. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2681 · Cited by 17
Physician Nutrition Advice and Referrals to Registered Dietitians
Pojednic, R. M., Phillips, E. M., Shehadeh, A., Muller, A., & Metallinos‐Katsaras, E. S. (2022) · American Journal of Lifestyle Medicine · doi:10.1177/15598276221092304 · Cited by 21
Zou, Q., Su, C., Du, W., Ouyang, Y., Wang, H., Zhang, B., Luo, S., Tan, T., Chen, Y., Zhong, X., et al. (2023) · Nutrients · doi:10.3390/nu15143113 · Cited by 15
Duell, P. B., Banach, M., Catapano, A. L., Laufs, U., Mancini, G. B. J., Ray, K. K., Broestl, C., Zhang, Y., Lei, L., & Goldberg, A. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.12.005 · Cited by 21
Sarzani, R., Landolfo, M., Pentima, C. D., Ortensi, B., Falcioni, P., Sabbatini, L., Massacesi, A., Rampino, I., Spannella, F., & Giulietti, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365183 · Cited by 26
Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia
Wichaiyo, S., & Supharattanasitthi, W. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01075-w · Cited by 17
“The recommended dose of bempedoic acid is 180 mg once daily [35].”
BackgroundGlycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 21
Trends and disparities in lipoprotein(a) testing in a large integrated US health system, 2000–23
Faaborg-Andersen, C. C., Cho, S. M. J., Natarajan, P., & Honigberg, M. C. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae155 · Cited by 14
Evinacumab for treatment of familial hypercholesterolemia
Warden, B. A., & Duell, P. B. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955349 · Cited by 16
Schade, D. S., Gonzales, K. M., Kaminsky, N. I., Adolphe, A., Shey, L., & Eaton, R. P. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.09.004 · Cited by 16
Brinton, E. A. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316893 · Cited by 16
Self-citationLipoprotein(a): cardiovascular risk and emerging therapies
Fujino, M., & Nicholls, S. J. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2197593 · Cited by 15
Zhou, J., & Wang, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107387 · Cited by 15
Shapiro, M. D., Haddad, T. M., WEINTRAUB, H. S., Baum, S. J., Abdul-Nour, K., Sarwat, S., Paluy, V., Boatwright, W., Browne, A., Ayaz, I., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.007 · Cited by 17
Lan, N. S. R., Bell, D. A., Watts, G. F., & Fegan, P. G. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000790 · Cited by 13
“Although some individuals may be considered very high-risk by some guidelines, they may be at low 10-year ASCVD risk (<10%) according to the Steno Type 1 Risk Engine and QRISK3 calculators [16,17,37,38].”
BackgroundExpanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Lee, J., & Lee, S. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.243 · Cited by 17
“…Society (ESC/EAS) guidelines [18], the American Association of Clinical Endocrinologists and American College of Endo-crinology (AACE) guidelines [19], and the Endocrine Society Clinical Practice Guidelines [20] encourage reducing LDL-C and non-HDL-C levels to targeted thresholds based on a…”
BackgroundLiang, J., Li, W., Liu, H., Li, X., Yuan, C., Zou, W., & Qu, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.857092 · Cited by 12
Loh, W. J., & Watts, G. F. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000789 · Cited by 12
Orfanos, P., Fonseca, A. F., Hu, X., Gautam, R., Montgomery, G., Studer, R. L., Kaur, J., Saxena, N., & Kaushik, N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294250 · Cited by 13
“…Heart Association (ACC/AHA), Canadian Cardiovascular Society (CCS), American Association of Clinical Endocrinologists (AACE), and American College of Endocrinology (ACE) suggest Lp(a) values of � 50 mg/dL, � 100 nmol/L, or � 125 nmol/L as clinically relevant elevated Lp(a) thresholds [9,10].”
BackgroundCardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
Self-citationMyerson, M. L., Paparodis, R. D., Block, R., Karalis, D. G., Mintz, G. L., Brinton, E. A., & Wild, R. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.04.131 · Cited by 19
Self-citationChianelli, M., Armellini, M., Carpentieri, M. S., Coccaro, C., Cuttica, C. M., Fusco, A., Marucci, S., Nelva, A., Nizzoli, M., Ponziani, M. C., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303282327240507184902 · Cited by 15
Ribero, V. A., Efthimiou, O., Abolhassani, N., Alwan, H., Bauer, D. C., Henrard, S., Christiaens, A., O’Mahony, D., Knol, W., Peters, M. J. L., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14340 · Cited by 12
SEA 2024 Standards for Global Control of Vascular Risk
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.06.001 · Cited by 18
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
McQueen, R. B., Baum, S. J., Louie, M. J., Sasiela, W. J., Bilitou, A., Shah, H., Nash, B., Gillard, K. K., & Ray, K. K. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00552-7 · Cited by 15
“Recent treatment guidelines and consensus statements recommend that based on the level of LDL-C lowering required to reach their goal, non-statin treatments may be added to maximally tolerated statins [5, 17, 18].”
BackgroundHuang, H., Xie, J., Hou, L., Miao, M., Xu, L., & Xu, C. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14133 · Cited by 11
“The normal range of LDL-C was de fi ned as < 100 mg/dL 29 .”
BackgroundLow prevalence of testing for apolipoprotein B and lipoprotein (a) in the real world
Murdock, D. J., Moll, K., Sanchez, R. J., Gu, J., Fazio, S., Geba, G. P., & Rodríguez, F. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100721 · Cited by 12
“As such, recent global guidelines and consensus statements recommend testing for ApoB and Lp(a) in certain circumstances [1-4].”
BackgroundSelf-citationPaliares, I. C., Dualib, P. M., Torres, L. S. N., Aroucha, P. M. T., de Almeida-Pititto, B., de Sá, J. R., & Dib, S. A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02460-3 · Cited by 14
“T1D exhibits heterogeneity, with certain individuals, particularly young ones, that may manifest a low or moderate CV risk [9, 10].”
BackgroundLolekha, P., Khovidhunkit, W., Deerochanawong, C., Thongtang, N., Boonyasirinant, T., Rattarasarn, C., Chutinet, A., Ophascharoensuk, V., Somlaw, N., Sitthisook, S., et al. (2024) · Asian Biomedicine · doi:10.2478/abm-2024-0033 · Cited by 21
Global lipoprotein (a) testing trends from 2015 to 2023
Hanif, M., Khan, L. A., Kulkarni, A., Bhatia, H. S., Wilkinson, M. J., Rashid, A. M., Chew, N., Banerjee, S., Butler, J., Shapiro, M. D., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.06.010 · Cited by 11
McCormick, D., Bhatt, D. L., Bays, H. E., Taub, P. R., Caldwell, K. A., Guerin, C. K., Steinhoff, J. P., Ahmad, Z., Singh, R. M., Moreo, K., et al. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.12.1517 · Cited by 11
Self-citationLeow, Y., Chan, W., Goh, G. B., Wong, V. W., Fan, J., Kim, Y. S., Kim, S. U., Nakajima, A., Seto, W., Lee, I., et al. (2023) · Journal of Viral Hepatitis · doi:10.1111/jvh.13796 · Cited by 11
“Moderate CVD risk n (%) 16/70 (23) 28/117 (24) 118/627 (19) 0.”
Shi, R., Gao, Y., Shen, L.-L., Shi, K., Wang, J., Li, J., Li, Y., & Yang, Z.-G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01556-y · Cited by 10
“Atherosclerotic cardiovascular disease (ASCVD) risk categories and corresponding LDL-C treatment goals were assessed according to the AACE/ACE consensus statement [10].”
Method
Metadata
- Authors
- Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., Garber, A. J., Grunberger, G., Krauss, R. M., Mechanick, J. I., Rosenblit, P. D., Smith, D. A., & Wyne, K. L.
- Affiliations
- University of Miami (US)
- University of California San Diego (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of California, Los Angeles (US)
- University of Chicago (US)
- Oregon Health & Science University (US)
- Tulane University (US)
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California, San Francisco (US)
- University of California, Irvine (US)
- The Ohio State University Wexner Medical Center (US)
- Corresponding author
- Handelsman, Yehuda
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 26
- Issue
- 10
- Pages
- 1196-1224
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3095590613
- Cited by
- 248
- References
- 130
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 58 · 2023: 50 · 2022: 57 · 2021: 26 · 2020: 1
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- dyslipidemia management, atherosclerotic cardiovascular disease prevention, LDL cholesterol targets, high-intensity statin therapy, PCSK9 inhibitors, ezetimibe, colesevelam, bempedoic acid, triglyceride-lowering therapy, fibrates, omega-3 fatty acids, nicotinic acid, icosapent ethyl, lipoprotein(a), statin intolerance, lifestyle therapy, cardiovascular risk stratification
- MeSH terms
- Endocrinologists, Algorithms, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Risk Factors, United States, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Consensus, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.